Nutriband Advances Abuse-Deterrent Fentanyl Patch Development Following Annual Meeting

Nutriband Inc. provided shareholders with an update following its 2026 Annual Shareholders Meeting, highlighting the appointment of two new directors and outlining key progress in the development of AVERSA Fentanyl. The company strengthened its exclusive partnership with Kindeva during 2025, completed commercial manufacturing scale-up, and expanded global patent protection including new U.S. and Macao patents.

The company engaged with the U.S. Food and Drug Administration through a Type C meeting and advanced branding initiatives for AVERSA Fentanyl. Nutriband’s lead product under development is an abuse-deterrent fentanyl patch incorporating AVERSA technology, which can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Looking ahead to 2026, Nutriband plans to advance toward an NDA filing by extending patent protection potentially to 2046, manufacturing clinical supplies, filing an Investigational New Drug application, and initiating a Human Abuse Liability clinical study. The company’s progress comes amid growing concerns about opioid abuse and the need for safer pain management alternatives.

The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB. BioMedWire, which published the original announcement, is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. For more information about BioMedWire, please visit https://www.BioMedWire.com.

The development of abuse-deterrent formulations represents a critical advancement in addressing the ongoing opioid crisis. By making it more difficult to extract and misuse fentanyl from transdermal patches, AVERSA technology could help prevent both intentional abuse and accidental exposure, particularly among vulnerable populations including children and individuals with substance use disorders.

Nutriband’s progress through regulatory channels and patent expansion demonstrates the company’s commitment to bringing this technology to market. The planned Human Abuse Liability study will provide important data on the product’s effectiveness in deterring misuse, while the extended patent protection through 2046 could provide substantial market exclusivity if the product receives FDA approval.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Nutriband Advances Abuse-Deterrent Fentanyl Patch Development Following Annual Meeting.

The post Nutriband Advances Abuse-Deterrent Fentanyl Patch Development Following Annual Meeting appeared first on citybuzz.